Top Medical News
Jairia Dela Cruz, 39 minutes ago
Type 2 diabetes mellitus (T2DM) contributes to a heightened risk of death, hepatic decompensation, and hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and cirrhosis, but the good news is that metformin may cut the risk of these adverse outcomes, a study has found.
2 hours ago
HbA1c grading influences the risk of developing isoniazid resistance and multidrug resistance (MDR) in tuberculosis (TB) infected patients with type 2 diabetes mellitus (T2DM), a study suggests.
Pearl Toh, 13 hours ago
Once-daily 14 mg oral semaglutide yields greater reduction in HbA1c and body weight than weekly 0.75 mg subcutaneous dulaglutide and is well tolerated in a Japanese population with uncontrolled type 2 diabetes (T2D), according to the PIONEER 10 study.
Roshini Claire Anthony, 18 hours ago

There is a high incidence of psychiatric comorbidities among gender nonconforming teenagers, with about two-thirds and one-third experiencing depression and anxiety, respectively, according to a study presented at ENDO 2020.

19 hours ago
Treatment with 15 mCi of radioiodine (RAI) leads to low hypothyroidism rates in adult patients with toxic multinodular goiter (TMNG), with high cure rates and significant volume reduction, according to a study. This effect persists in the long term.
21 hours ago
The glucagon-like peptide-1 (GLP-1) receptor agonist (RA) dulaglutide shows highly consistent effectiveness on glycated haemoglobin (HbA1c) and body weight reduction in patients with type 2 diabetes (T2D), reveals a study. Its effectiveness remains significant even in subgroups of patients poorly represented in randomized controlled trials (RCTs).
Yesterday
In conscious type 1 diabetes mellitus (T1DM) patients, administering glucagon intranasally is as effective at resolving hypoglycaemia as administering it via intramuscular/subcutaneous injections, according to the results of a meta-analysis.
Special Reports
11 May 2020
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.
Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

08 Apr 2020
This is the first issue in a series of five articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data release. This issue brings insight to the trial’s background, study design and key results.
10 Mar 2020
In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.
26 Feb 2020
At the AstraZeneca sponsored-symposium, held in conjunction with Diabetes Asia 2019, a panel of distinguished speakers spoke about the importance of preventing cardiovascular (CV) and renal complications in patients with type 2 diabetes mellitus (T2DM), in addition to addressing glucose control. Chaired by Professor Dato’ Dr Mafauzy Mohamed, the panel discussed updated outcomes of landmark studies supporting the benefit of dapagliflozin (Forxiga®, AstraZeneca) in patients with T2DM.
24 Feb 2020
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).
29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Conference Reports
Roshini Claire Anthony, 03 Jun 2020

There is a high incidence of psychiatric comorbidities among gender nonconforming teenagers, with about two-thirds and one-third experiencing depression and anxiety, respectively, according to a study presented at ENDO 2020.

Roshini Claire Anthony, 28 May 2020

A study from South Korea, presented at ENDO 2020, suggested that individuals who work long hours may be at risk of developing hypothyroidism.

Elaine Soliven, 21 Apr 2020
Adding liraglutide to first-line lifestyle therapy led to a significantly reduced BMI standard-deviation score (BMI SDS*) among obese adolescents who failed to respond to lifestyle therapy alone, according to a study presented at ENDO 2020.
Audrey Abella, 14 Apr 2020
The investigational, oral formulation of octreotide appeared to be effective and safe as maintenance treatment for adults with acromegaly, according to the results of the phase III OPTIMAL* study presented at ENDO 2020.
Pearl Toh, 13 Apr 2020
Use of thyroid replacement therapy in older people with isolated elevations in TSH* was associated with a significantly increased risk of death than those who were left untreated, according to the BLSA** study presented at ENDO 2020 — which raises the possibility of overtreatment in these older adults.
Audrey Abella, 09 Apr 2020
The human monoclonal anti-IGF-1R* antibody teprotumumab was effective in reducing proptosis or eye bulging in patients with the rare thyroid eye disease (TED) regardless of age, gender, and/or smoking status, according to pooled data presented at ENDO 2020.
Pearl Toh, 08 Apr 2020
Maintaining a good control of blood glucose level may slow down the decline of cognitive function in patients with type 2 diabetes (T2D) after a lacunar stroke, suggests a post hoc analysis of the SPS3* trial presented at the ENDO 2020 Virtual Meeting.
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download